Ivana Barravecchia

Ivana Barravecchia

Auto-generated profile, based on publicly available information

Ivana Barravecchia

Center for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
MSMonika Sharma
Monika Sharma
IBIvana Barravecchia
Ivana Barravecchia
RTRobert Teis
Robert Teis
JCJeanette Cruz
Jeanette Cruz
RMRachel Mumby
Rachel Mumby
SGStefanie Galban
Stefanie Galban
Therapeutic resistance remains a major obstacle to successful clinical management of diffuse intrinsic pontine glioma (DIPG), a high-grade pediatric tumor of the brain stem. In nearly all patients, available therapies fail to prevent progression. Innovative combinatorial therapies that penetrate the blood–brain barrier and lead to long-term control of tumor growth are desperately needed. We identified mechanisms of resistance to radiotherapy, the standard of care for DIPG. On the basis of these findings, we rationally designed a brain-penetrant small molecule, MTX-241F, that is a highly selective inhibitor of EGFR and PI3 kinase family members, including the DNA repair protein DNA-PK. Preliminary studies demonstrated that micromolar levels of this inhibitor can be achieved in murine brain tissue and that MTX-241F exhibits promising single-agent efficacy and radiosensitizing activity in patient-derived DIPG neurospheres. Its physiochemical properties include high exposure in the brain, indicating excellent brain penetrance. Because radiotherapy results in double-strand breaks that are repaired by homologous recombination (HR) and non-homologous DNA end joining (NHEJ), we have tested the combination of MTX-241F with an inhibitor of Ataxia Telangiectasia Mutated to achieve blockade of HR and NHEJ, respectively, with or without radiotherapy. When HR blockers were combined with MTX-241F and radiotherapy, synthetic lethality was observed, providing impetus to explore this combination in clinically relevant models of DIPG. Our data provide proof-of-concept evidence to support advanced development of MTX-241F for the treatment of DIPG. Future studies will be designed to inform rapid clinical translation to ultimately impact patients diagnosed with this devastating disease.

28 November 2023 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
IBIvana Barravecchia
Ivana Barravecchia
JLJennifer M. Lee
Jennifer M. Lee
JMJason Manassa
Jason Manassa
BMBrian Magnuson
Brian Magnuson
SFSarah F. Ferris
Sarah F. Ferris
SGStefanie Galban
Stefanie Galban
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive, often fatal loss of lung function due to overactive collagen production and tissue scarring. Patients with IPF have a sevenfold-increased risk of developing lung cancer. The COVID-19 pandemic has increased the number of patients with lung diseases, and infection can worsen prognoses for those with chronic lung diseases and disease-associated cancer. Understanding the molecular pathogenesis of IPF-associated lung cancer is imperative for identifying diagnostic biomarkers and targeted therapies that will facilitate prevention of IPF and progression to lung cancer. To understand how IPF-associated fibroblast activation, matrix remodeling, epithelial-to-mesenchymal transition (EMT), and immune modulation influences lung cancer predisposition, we developed a mouse model to recapitulate the molecular pathogenesis of pulmonary fibrosis–associated lung cancer using the bleomycin and Lewis lung carcinoma models. We demonstrate that development of pulmonary fibrosis–associated lung cancer is likely linked to increased abundance of tumor-associated macrophages and a unique gene signature that supports an immune-suppressive microenvironment through secreted factors. Not surprisingly, preexisting fibrosis provides a pre-metastatic niche and results in augmented tumor growth, and tumors associated with bleomycin-induced fibrosis are characterized by a dramatic loss of cytokeratin expression, indicative of EMT. Implications: This characterization of tumors associated with lung diseases provides new therapeutic targets that may aid in the development of treatment paradigms for lung cancer patients with preexisting pulmonary diseases.

3 January 2024
Verified
Other
Open access
MSMonika Sharma
Monika Sharma
IBIvana Barravecchia
Ivana Barravecchia
RTRobert Teis
Robert Teis
JCJeanette Cruz
Jeanette Cruz
RMRachel Mumby
Rachel Mumby
SGStefanie Galban
Stefanie Galban
Therapeutic resistance remains a major obstacle to successful clinical management of diffuse intrinsic pontine glioma (DIPG), a high-grade pediatric tumor of the brain stem. In nearly all patients, available therapies fail to prevent progression. Innovative combinatorial therapies that penetrate the blood–brain barrier and lead to long-term control of tumor growth are desperately needed. We identified mechanisms of resistance to radiotherapy, the standard of care for DIPG. On the basis of these findings, we rationally designed a brain-penetrant small molecule, MTX-241F, that is a highly selective inhibitor of EGFR and PI3 kinase family members, including the DNA repair protein DNA-PK. Preliminary studies demonstrated that micromolar levels of this inhibitor can be achieved in murine brain tissue and that MTX-241F exhibits promising single-agent efficacy and radiosensitizing activity in patient-derived DIPG neurospheres. Its physiochemical properties include high exposure in the brain, indicating excellent brain penetrance. Because radiotherapy results in double-strand breaks that are repaired by homologous recombination (HR) and non-homologous DNA end joining (NHEJ), we have tested the combination of MTX-241F with an inhibitor of Ataxia Telangiectasia Mutated to achieve blockade of HR and NHEJ, respectively, with or without radiotherapy. When HR blockers were combined with MTX-241F and radiotherapy, synthetic lethality was observed, providing impetus to explore this combination in clinically relevant models of DIPG.Our data provide proof-of-concept evidence to support advanced development of MTX-241F for the treatment of DIPG. Future studies will be designed to inform rapid clinical translation to ultimately impact patients diagnosed with this devastating disease.


1 March 2024
Verified
Other
Open access
IBIvana Barravecchia
Ivana Barravecchia
JLJennifer M. Lee
Jennifer M. Lee
JMJason Manassa
Jason Manassa
BMBrian Magnuson
Brian Magnuson
SFSarah F. Ferris
Sarah F. Ferris
SGStefanie Galban
Stefanie Galban
Supplemental Figure S2. Expression of immune cell surface markers by CyTOF.

1 March 2024
Verified
Other
Open access
PDF file
IBIvana Barravecchia
Ivana Barravecchia
JLJennifer M. Lee
Jennifer M. Lee
JMJason Manassa
Jason Manassa
BMBrian Magnuson
Brian Magnuson
SFSarah F. Ferris
Sarah F. Ferris
SGStefanie Galban
Stefanie Galban
Supplemental Figure S1. Transgenic mouse IPF-LC model development.